OncoLens key facts
- Developer of a HIPAA-compliant mobile and web-based platform designed for targeted treatment planning and confident clinical decision-making.
- OncoLens’s last known valuation is $54.0M.
- It has raised $22.9M; the latest was Later Stage VC ($15.0M) in Oct 2024.
- Notable investors include Martin Ventures, Atlanta Technology Angels, BIP Ventures, Cross Border Impact Ventures, Robbins Fund — 6 tracked in total.
- Status: Privately Held (backing).
- ·Watch OncoLens: the Monday email on marks, rounds and moves
OncoLens funding rounds
No funding rounds for OncoLens are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
OncoLens valuation
OncoLens's last known valuation is $54 million. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.
OncoLens investors
6 investors are on record for OncoLens, including Martin Ventures, Atlanta Technology Angels, BIP Ventures and Cross Border Impact Ventures.
About OncoLens
Developer of a HIPAA-compliant mobile and web-based platform designed for targeted treatment planning and confident clinical decision-making. The company's platform brings disparate data sets, oncology care teams, and stakeholders into a singular platform to drive multidisciplinary treatment planning, life-science commercial and clinical efforts, and payer authorizations, enabling the physicians to create a tumor board and discuss treatment plans for cancer patients.
- Sector
- Healthcare
- HQ
- Atlanta, GA, United States
- Founded
- 2017
- Employees
- 28
- Website
- oncolens.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
OncoLens’s last known valuation. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.